Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q3 2014 · 10-Q
Revenue$28.26M$28.26M−17.5% vs Q3 2013 Net Income-$4.45M-$4.45MN/M vs Q3 2013 EPS Diluted-$0.29-$0.29N/M vs Q3 2013 Gross Profit$3,854,000−17.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived$322,000−60.3% Free Cash Flowderived-$116,000N/M Margins · derivedGross margin13.6%−0.1 pt vs Q3 2013
Operating margin-11.3%−5.3 pt vs Q3 2013
Net margin-15.8%−9.5 pt vs Q3 2013
ended Sep 30, 2014 · filed Nov 5, 2014 · 36 d after period end